DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $14.75.
Several research analysts have weighed in on the stock. Lifesci Capital upgraded shares of DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. JMP Securities reiterated a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research report on Thursday, June 26th. Wall Street Zen cut shares of DBV Technologies from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 price objective on the stock in a research note on Thursday, May 29th. Finally, Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th.
Check Out Our Latest Stock Report on DBV Technologies
DBV Technologies Trading Up 0.1%
DBVT stock traded up $0.01 on Wednesday, hitting $9.88. 5,772 shares of the company's stock traded hands, compared to its average volume of 187,351. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78. The stock has a fifty day moving average of $9.73 and a 200-day moving average of $8.55. The stock has a market cap of $270.58 million, a price-to-earnings ratio of -2.07 and a beta of -0.36.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. On average, equities research analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current fiscal year.
Hedge Funds Weigh In On DBV Technologies
Institutional investors and hedge funds have recently modified their holdings of the stock. Nan Fung Trinity HK Ltd. bought a new stake in shares of DBV Technologies in the second quarter valued at about $340,000. Octagon Capital Advisors LP bought a new position in shares of DBV Technologies in the second quarter worth about $9,315,000. MPM Bioimpact LLC acquired a new position in shares of DBV Technologies in the second quarter valued at approximately $9,649,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of DBV Technologies in the second quarter valued at approximately $9,659,000. Finally, Vivo Capital LLC acquired a new stake in DBV Technologies during the 2nd quarter valued at approximately $9,659,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Further Reading
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
